BofA spends $250M annually on Ozempic for staff, raising corporate health stakes
Bank of America now pays over $250 million each year to cover GLP‑1 weight‑loss drugs such as Ozempic and Wegovy for its 211,000 employees. CEO Brian Moynihan says the spend, about 13 % of the bank’s $2 billion health budget, is justified by improved employee health and lower long‑term costs, even as other employers wrestle with soaring drug prices.